Literature DB >> 27464795

Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.

Alaa Tarig Alshareeda1,2, Ola H Negm3,4, Mohammed A Aleskandarany1,5, Andrew R Green1, Christopher Nolan1, Patrick J TigHhe3, Srinivasan Madhusudan1, Ian O Ellis1, Emad A Rakha1.   

Abstract

Impaired DNA damage response (DDR) may play a fundamental role in the pathogenesis of breast cancer (BC). RAD51 is a key player in DNA double-strand break repair. In this study, we aimed to assess the biological and clinical significance of RAD51 expression with relevance to different molecular classes of BC and patients' outcome. The expression of RAD51 was assessed immunohistochemically in a well-characterised annotated series (n = 1184) of early-stage invasive BC with long-term follow-up. A subset of cases of BC from patients with known BRCA1 germline mutations was included as a control group. The results were correlated with clinicopathological and molecular parameters and patients' outcome. RAD51 protein expression level was also assayed in a panel of cell lines using reverse phase protein array (RPPA). RAD51 was expressed in the nuclei (N) and cytoplasm (C) of malignant cells. Subcellular co-localisation phenotypes of RAD51 were significantly associated with clinicopathological features and patient outcome. Cytoplasmic expression (RAD51C(+)) and lack of nuclear expression (RAD51 N(-)) were associated with features of aggressive behaviour, including larger tumour size, high grade, lymph nodal metastasis, basal-like, and triple-negative phenotypes, together with aberrant expression of key DDR biomarkers including BRCA1. All BRCA1-mutated tumours had RAD51C(+)/N(-) phenotype. RPPA confirmed IHC results and showed differential expression of RAD51 in cell lines based on ER expression and BRCA1 status. RAD51 N(+) and RAD51C(+) tumours were associated with longer and shorter breast cancer-specific survival (BCSS), respectively. The RAD51 N(+) was an independent predictor of longer BCSS (P < 0.0001). Lack of RAD51 nuclear expression is associated with poor prognostic parameters and shorter survival in invasive BC patients. The significant associations between RAD51 subcellular localisation and clinicopathological features, molecular subtype and patients' outcome suggest that the trafficking of DDR proteins between the nucleus and cytoplasm might play a role in the development and progression of BC.

Entities:  

Keywords:  BRCA-mutated breast cancers; DNA damage response; DNA repair; Immunohistochemistry; RAD51; Reverse phase protein array

Mesh:

Substances:

Year:  2016        PMID: 27464795     DOI: 10.1007/s10549-016-3915-8

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  15 in total

1.  The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP/TAZ-mediated Rad51 expression.

Authors:  Ameer L Elaimy; John J Amante; Lihua Julie Zhu; Mengdie Wang; Charlotte S Walmsley; Thomas J FitzGerald; Hira Lal Goel; Arthur M Mercurio
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-24       Impact factor: 11.205

2.  β1-Integrin Impacts Rad51 Stability and DNA Double-Strand Break Repair by Homologous Recombination.

Authors:  Kazi Mokim Ahmed; Raj K Pandita; Dharmendra Kumar Singh; Clayton R Hunt; Tej K Pandita
Journal:  Mol Cell Biol       Date:  2018-04-16       Impact factor: 4.272

3.  Prognostic Value of the Immunohistochemical Expression of RAD51 and BRCA2 in Gastric Adenocarcinoma.

Authors:  Joel Del Bel Pádua; Carolline Fontes Alves Mariano; Alexandre Todorovic Fabro; Daniela Pretti da Cunha Tirapelli; Ajith Kumar Sankarankutty; José Sebastião Dos Santos; Mariângela Ottoboni Brunaldi
Journal:  J Histochem Cytochem       Date:  2022-01-03       Impact factor: 2.479

4.  Dynamin impacts homology-directed repair and breast cancer response to chemotherapy.

Authors:  Sophia B Chernikova; Rochelle B Nguyen; Jessica T Truong; Stephano S Mello; Jason H Stafford; Michael P Hay; Andrew Olson; David E Solow-Cordero; Douglas J Wood; Solomon Henry; Rie von Eyben; Lei Deng; Melanie Hayden Gephart; Asaithamby Aroumougame; Claudia Wiese; John C Game; Balázs Győrffy; J Martin Brown
Journal:  J Clin Invest       Date:  2018-10-29       Impact factor: 14.808

Review 5.  DNA damage repair functions and targeted treatment in breast cancer.

Authors:  Chenfeng He; Kosuke Kawaguchi; Masakazu Toi
Journal:  Breast Cancer       Date:  2020-01-02       Impact factor: 4.239

6.  Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer.

Authors:  Michal M Hoppe; Patrick Jaynes; Joanna D Wardyn; Sai Srinivas Upadhyayula; Tuan Zea Tan; Stefanus Lie; Diana G Z Lim; Brendan N K Pang; Sherlly Lim; Joe P S Yeong; Anthony Karnezis; Derek S Chiu; Samuel Leung; David G Huntsman; Anna S Sedukhina; Ko Sato; Monique D Topp; Clare L Scott; Hyungwon Choi; Naina R Patel; Robert Brown; Stan B Kaye; Jason J Pitt; David S P Tan; Anand D Jeyasekharan
Journal:  EMBO Mol Med       Date:  2021-03-11       Impact factor: 12.137

Review 7.  Association between RAD51 135 G/C polymorphism and risk of 3 common gynecological cancers: A meta-analysis.

Authors:  Xianling Zeng; Yafei Zhang; Lei Yang; Huiqiu Xu; Taohong Zhang; Ruifang An; Kexiu Zhu
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

8.  Gene prioritization, communality analysis, networking and metabolic integrated pathway to better understand breast cancer pathogenesis.

Authors:  Andrés López-Cortés; César Paz-Y-Miño; Alejandro Cabrera-Andrade; Stephen J Barigye; Cristian R Munteanu; Humberto González-Díaz; Alejandro Pazos; Yunierkis Pérez-Castillo; Eduardo Tejera
Journal:  Sci Rep       Date:  2018-11-12       Impact factor: 4.379

9.  Nuclear rupture at sites of high curvature compromises retention of DNA repair factors.

Authors:  Yuntao Xia; Irena L Ivanovska; Kuangzheng Zhu; Lucas Smith; Jerome Irianto; Charlotte R Pfeifer; Cory M Alvey; Jiazheng Ji; Dazhen Liu; Sangkyun Cho; Rachel R Bennett; Andrea J Liu; Roger A Greenberg; Dennis E Discher
Journal:  J Cell Biol       Date:  2018-08-31       Impact factor: 10.539

Review 10.  Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer.

Authors:  Nan Wu; Jinghua Zhang; Jing Zhao; Kun Mu; Jun Zhang; Zhao Jin; Jinpu Yu; Juntian Liu
Journal:  Oncol Lett       Date:  2018-08-10       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.